Penumbra (NYSE:PEN) Stock Rating Lowered by Zacks Investment

Penumbra (NYSE:PEN – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Friday, Zacks.com reports. According to Zacks, “Penumbra, Inc. is an interventional therapies company. It designs, develops, manufactures and markets medical devices. The company’s portfolio of products […]

Related Keywords

Australia , California , United States , Blackrock , Canada , Surbhi Sarna , Johanna Roberts , Penumbra Inc , Geode Capital Management , Zacks Investment Research , Blackrock Inc , Champlain Investment Partners , Jpmorgan Chase Co , William Blair Investment Management , Canaccord Genuity Group , Get Rating , Neurovascular Access , Neuron Access System , Access System , Penumbra System , Penumbra Coil , Ruby Coil System , Penumbra Occlusion Device , Director Surbhi Sarna , Blair Investment Management , Street Corp , Investment Partners , Capital Management , Penumbra , Nyse Pen , Pen , Medical , Downgrade ,